Markets:

Overview

News

Currencies

International

Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

6.930 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors

June 20, 2024

From ImmunityBio, Inc.

Via Business Wire

3 Short-Squeeze Stocks Outwitting the Pessimistic Predictions ↗

June 20, 2024

Don't be discouraged by the bears. Here are my three picks of short-squeeze stocks to buy for investors everywhere.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 11, 2024

Via Benzinga

How Is The Market Feeling About ImmunityBio? ↗

May 17, 2024

Via Benzinga

Check Out What Whales Are Doing With IBRX ↗

April 30, 2024

Via Benzinga

ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update

June 07, 2024

From ImmunityBio, Inc.

Via Business Wire

These 3 Interesting Stocks Are Seeing Heavy Short Interest In June 2024 ↗

June 04, 2024

Economic slowdown meets short-selling speculations. Candidates for incoming market volatility are here.

Via Talk Markets

Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

May 17, 2024

From ImmunityBio, Inc.

Via Business Wire

Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months ↗

May 13, 2024

In the last three months, IBRX outperformed NVDA by over 3x.

Via Talk Markets

IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024 ↗

May 10, 2024

IBRX stock results show that ImmunityBio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

The 3 Best Bargain Stocks to Buy in May 2024 ↗

May 09, 2024

There are several types of bargain stocks for investors to consider. Here are the three best bargain stocks to buy now.

Via InvestorPlace

Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday ↗

May 07, 2024

Via Benzinga

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®

May 07, 2024

From ImmunityBio, Inc.

Via Business Wire

Even Worse than Gamestop? 3 Meme Stocks That Are Screaming Sells ↗

May 06, 2024

Here are just a few of the top meme stocks to sell immediately. In fact, I wouldn't waste investment dollars on any.

Via InvestorPlace

Serum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio's Bladder Cancer Combo Therapy ↗

May 03, 2024

Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to expand BCG supply. FDA-approved Anktiva plus BCG for bladder cancer.

Via Benzinga

Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday ↗

May 03, 2024

Via Benzinga

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types

May 02, 2024

From ImmunityBio, Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

May 02, 2024

Via Benzinga

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association

April 30, 2024

From ImmunityBio, Inc.

Via Business Wire

Stocks Quietly Climb Ahead Of Central Bank Storm ↗

April 29, 2024

The Dow Jones Industrial Average, Nasdaq Composite, and S&P 500 Index are all sporting comfortable leads this afternoon.

Via Talk Markets

Topics Economy Stocks

Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

April 29, 2024

Via Benzinga

Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday ↗

April 29, 2024

Via Benzinga

Why Philips Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket ↗

April 29, 2024

Via Benzinga

What's Going On With ImmunityBio Stock? ↗

April 26, 2024

ImmunityBio said the QUILT 3.055 trial shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 26, 2024

Via Benzinga

Why Teradyne Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket ↗

April 25, 2024

Via Benzinga

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

April 25, 2024

From ImmunityBio, Inc.

Via Business Wire

FDA Approves ImmunityBio's Bladder Cancer Drug, Stock Rallies ↗

April 23, 2024

FDA approves ImmunityBio's Anktiva plus Bacillus Calmette-Guérin for BCG-unresponsive non-muscle invasive bladder cancer. Anktiva shows promising complete response rates and duration exceeding 24...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 23, 2024

Via Benzinga

Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket ↗

April 23, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

All News about ImmunityBio, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today